The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)
Open accessAbstract
Guidelines for the clinical management of patients with neurocysticercosis (NCC) were prepared by a panel of the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). The guidelines are intended for infectious disease specialists, neurologists, neurological surgeons, internists, pediatricians, and family practitioners. These guidelines present our approaches to the diagnosis and management of patients with the different forms of neurocysticercosis, including viable parenchymal neurocysticercosis, single enhancing lesions, calcified parenchymal neurocysticercosis, ventricular neurocysticercosis, and subarachnoid neurocysticercosis. Our recommendations are based on the best evidence available. Due to the complex variations in clinical manifestations and the limitations of the literature, many of the recommendations are based on observational studies, anecdotal data, or expert opinion rather than randomized clinical trials. The approaches we describe are intended to be both applicable and feasible in the United States and Canada (for simplicity, referred to here as North America). The recommendations may not apply for settings where resource constraints may limit their applicability. The executive summary below lists the recommendations for the diagnosis and clinical management of neurocysticercosis. A detailed description of the methods, background, and evidence summaries that support each of the recommendations can be found online in the full text of the guidelines. A criterion for grading evidence is presented in Figure 1 [1]. Note that diagnosis and management of patients with neurocysticercosis can be challenging even with expert guidelines. Due to this complexity, clinicians with little experience with this disease should have a low threshold for consultation with an expert in the disease. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework for grading of evidence. While there is a wide range of clinical manifestations of neurocysticercosis, the 2 most common clinical presentations are with seizures and increased intracranial pressure (not graded). Initial evaluation should include careful history and physical examination, and neuroimaging studies (not graded). We recommend serologic testing with enzyme-linked immunotransfer blot as a confirmatory test in patients with suspected neurocysticercosis (strong, moderate). Enzyme-linked immunosorbent assays using crude antigen should be avoided due to poor sensitivity and specificity (strong, moderate). 4. We recommend both brain magnetic resonance imaging (MRI) and a noncontrast computed tomography (CT) scan for classifying patients with newly diagnosed neurocysticercosis (strong, moderate). The classification is outlined in Table 1. 5. We suggest screening for latent tuberculosis infection in patients likely to require prolonged corticosteroids (weak, low). 6. We suggest screening or empiric therapy for Strongyloides stercoralis in patients likely to require prolonged corticosteroids (weak, low). 7. We recommend that all patients with NCC undergo a funduscopic examination prior to initiation of anthelminthic therapy (strong, moderate). 8. We suggest that patients with NCC who probably acquired NCC in a nonendemic area have their household members screened for tapeworm carriage (weak, low). Remark: This is a public health issue and can often be addressed by the local health department. 9. We recommend that patients treated with albendazole for >14 days be monitored for hepatotoxicity and leukopenia (strong, moderate). 10. No additional monitoring is needed for patients receiving combination therapy with albendazole and praziquantel beyond that recommended for albendazole monotherapy (strong, moderate). 11. In patients with untreated hydrocephalus or diffuse cerebral edema, we recommend management of elevated intracranial pressure alone and not antiparasitic treatment (strong, moderate). Remarks: The management of patients with diffuse cerebral should be therapy as hydrocephalus a In the of elevated intracranial we recommend of antiparasitic in all patients with (strong, patients with viable parenchymal we recommend albendazole monotherapy for days to antiparasitic therapy (strong, or combination antiparasitic therapy (weak, moderate). Remarks: The of albendazole is 2 for days with We recommend a of We recommend albendazole with praziquantel for days rather than albendazole monotherapy for patients with viable parenchymal (strong, moderate). We suggest with antiparasitic therapy for parenchymal for the of the of therapy (weak, low). We recommend therapy prior to antiparasitic rather than therapy in all patients treated with antiparasitic therapy (strong, moderate). We recommend in all NCC patients with seizures (strong, low). In patients with seizures prior to antiparasitic of the on imaging studies, and seizures for we suggest that and be (weak, moderate). In the of da
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology
Guyatt, G. H., Oxman, A. D., Schünemann, H. J., Tugwell, P., & Knottnerus, A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.011 · Cited by 3,094
Tsang, V. C. W., Brand, J. A., & Boyer, A. E. (1989) · The Journal of Infectious Diseases · doi:10.1093/infdis/159.1.50 · Cited by 836
Lewinsohn, D. M., Leonard, M. K., LoBue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw778 · Cited by 773
Clinical symptoms, diagnosis, and treatment of neurocysticercosis
Garcia, H. H., Nash, T. E., & Del Brutto, O. H. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70094-8 · Cited by 594
Self-citation(2000) · PubMed · Cited by 486
A Systematic Review of the Frequency of Neurocyticercosis with a Focus on People with Epilepsy
Ndimubanzi, P. C., Carabin, H., Budke, C. M., Nguyen, H., Qian, Y.-J., Rainwater, E., Dickey, M., Reynolds, S., & Stoner, J. A. (2010) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000870 · Cited by 478
Neurocysticercosis: a new classification based on active and inactive forms. A study of 753 cases
Sotelo, J. (1985) · Archives of Internal Medicine · doi:10.1001/archinte.145.3.442 · Cited by 430
A Trial of Antiparasitic Treatment to Reduce the Rate of Seizures Due to Cerebral Cysticercosis
Garcia, H. H., Pretell, E. J., Gilman, R. H., Martinez, S. M., Moulton, L. H., Del Brutto, O. H., Herrera, G., Evans, C. A. W., & Gonzalez, A. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031294 · Cited by 418
Self-citationDiagnosis and treatment of neurocysticercosis
Nash, T. E., & Garcia, H. H. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.135 · Cited by 253
Self-citation
Metadata
- Authors
- White, A. C., Coyle, C. M., Rajshekhar, V., Singh, G., Hauser, W. A., Mohanty, A., Garcia, H. H., & Nash, T. E.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-22
- Volume
- 66
- Issue
- 8
- Pages
- e49-e75
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4240368536
- Cited by
- 285
- References
- 59
- FWCI
- 8.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). https://app.cochat.ai/papers/10.1093/cid/cix1084
- The paper
- White, A. C., Coyle, C. M., Rajshekhar, V., Singh, G., Hauser, W. A., Mohanty, A., Garcia, H. H., & Nash, T. E. (2018). Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clinical Infectious Diseases. https://doi.org/10.1093/cid/cix1084
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.